Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study
Background and Objectives: A recent clinical trial has demonstrated that breast cancer with low-HER2 expression levels responds to trastuzumab deruxtecan treatment.This has prompted a re-evaluation of HER2-targeted therapies in the HER2-negative group.Further research is required in the form of more detailed information about HER2-negative breast c